The new facility is located in Amman, Jordan and is an extension to an existing active pharmaceutical ingredient (API) site, adjacent to the company’s headquarters.
The site was inaugurated last week by King Abdallah of Jordan and will produce the raw materials for Hikma’s pipeline.
“Currently we’ve 5 oncology APIs in the development pipelines,” Hikma spokesman Ben Atwell was able to tell in-Pharmatechnologist.com, though he did not reveal more information about the new site or how it would support Hikma’s API network.
In 2011, the firm invested $33m (€23m) in a joint venture with Indian API and intermediate firm Unimark Remedies in order to develop specialised APIs.
Recently the firm has been focusing on the sterile injectables market, having rebuffed offers to sell its ‘lucrative’ business last year to Amgen and Novartis, and buying Ohio-based Bedford Labs – and subsequently troubled manufacturer Ben Venue Labs - for $300m in May.